Nuclear Medicine Market

Q: How big was the global nuclear medicine market in 2024?

It was valued at US$ 18.6 Bn in 2024 Read More

Q: What is the projected size of the nuclear medicine market by 2035?

It is projected to cross US$ 57.3 Bn by the end of 2035 Read More

Nuclear Medicine Market (Product Type: Diagnostics Products and Therapeutic Products; Application: Cardiology, Neurology, Oncology, Thyroid, Lymphoma, Bone Metastasis, Endocrine Tumor and Others; and End-user: Hospitals and Clinics, Diagnostic Centers and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

Nuclear Medicine Market Outlook

The global nuclear medicine market was valued at US$ 18.6 Bn in 2024
The global nuclear medicine industry is projected to grow at a CAGR of 10.8% from 2025 to 2035 and reach US$ 57.3 Bn by the end of 2035

Analysts’ Viewpoint regarding nuclear medicine market

The nuclear medicine industry is experiencing historic growth due to advancing technology in imaging equipment combined with the rising incidence of chronic diseases.

Nuclear Medicine Market By Revenue

PET and SPECT imaging technologies are advancing, thereby increasing diagnostic capability, enabling early detection of disease like cancer and cardiovascular disease and hence treating them accordingly. In addition, an expanding geriatric population are fueling diagnostics demand, thereby also driving market growth.

However, growth will be constrained by regulatory problems and the cost of nuclear medicine tests. Unavailability of certain isotopes also creates supply chain challenges.

Nuclear Medicine Market Introduction

Nuclear medicine implies a medical imaging subspecialty that uses radiopharmaceuticals or radioactive medications to diagnose and treat disease. It is one of the valuable resources for the early diagnosis of diseases such as cardiovascular disease, cancer, and neurological disorders.

Nuclear medicine lets physicians to visualize the way tissues and organs are functioning by introducing small quantities of radioactive material into the body, thereby providing information not found using the other forms of standard imaging.

These tests are non-painful and may be performed by single photon emission computed tomography (SPECT) and positron emission tomography (PET). Apart from diagnosis, nuclear medicine is also delivered as targeted radionuclide therapy, with the potential to target cancer cells for selective destruction.

As technological advancements and radiopharmaceutical development go on a day-to-day basis, so does the field, with opportunities for more favorable outcomes and individually adapted treatment regimens. Combined, nuclear medicine makes a substantial contribution to healthcare in today's world, having a dramatic effect on the diagnosis and treatment of patients.

Attribute	Detail
Market Drivers	Growing Adoption of Hybrid Imaging Systems Increased Demand for Early and Accurate Diagnosis

Growing Adoption of Hybrid Imaging Systems Driving Nuclear Medicine Market Size

Rise in adoption of hybrid imaging systems is one of the key drivers to the nuclear medicine market owing to medical professionals being drawn to more advanced diagnostic methods. Hybrid imaging does combine two or more modalities such as positron emission tomography (PET) and computed tomography (CT) for creating both - functional and anatomical data in a single scan. This enables higher diagnostic accuracy whereby disease is localized precisely along with treatment planning.

While hospitals and imaging centers are spending more on new technology, hybrid systems are in greater demand than ever before. Not only are they ideal for cancer detection, but also for observing how a patient reacts to treatment and thus of very high value in oncology, cardiology, and neurology. That they also enhance workflow and reduce patient exposure to radiation just makes them all the more appealing.

The nuclear medicine sector is also experiencing tremendous growth on the account of these technological innovations coupled with a universal prevalence of chronic illnesses. As healthcare infrastructure worldwide focuses on early diagnosis and personalized care, the intersection of hybrid imaging solution and nuclear medicine will continue to be a prime determinant of nuclear medicine future, touting enhanced patient care and efficiency in medical imaging as a whole.

Increased Demand for Early and Accurate Diagnosis Bolstering Nuclear Medicine Market

Early and accurate diagnosis is one of the driving factors in nuclear medicine. Early diagnosis of diseases, particularly diseases like cancer, cardiovascular diseases, and neurological diseases, has become more pronounced in medical advancement. Nuclear medicine capitalizes on the application of radiopharmaceuticals for visualization of the body's metabolic processes and thus for physicians to find abnormalities early.

The ability to make timely and correct diagnosis is crucial for successful treatment planning and better patient outcomes. Both - the physician and the patient are well-versed with the advantages of detection of disease at an early stage, and thus there is a rising need for newer imaging techniques that nuclear medicine must deliver. A population boom of older individuals worldwide also creates the demand as patients who are old have a higher susceptibility toward chronic disease that needs to be searched frequently.

As a result, the nuclear medicine market is observed to be expanding rapidly, boosted by technological progress in imaging and new radiopharmaceuticals. Emphasis on pre-symptomatic diagnosis optimizes the efficacy of treatment as much as it fuels a move toward targeted or personalized medicine, where treatment can be tailored to meet the individual's specific requirements based on accurate diagnostic information.

Diagnostics Product Type leading Nuclear Medicine Market

Nuclear Medicine Market By Product Type

Diagnostic product solutions are leading the nuclear medicine market as they have a key function in detecting disease at an early stage and curing patients. These products, e.g., radiopharmaceuticals and scanners, enable physicians to image precisely physiological functions, thus helping physicians detect diseases such as cancer, cardiovascular diseases, and neurological diseases. The increasing incidence of chronic diseases and the increasing focus on preventive medicine are driving demand for more advanced diagnostic technology.

Innovation in imaging technologies such as PET and SPECT, which offer better quality of diagnosis and ease of use, is a key driver. Not only do these methods produce images of higher quality, but also reduce patient exposure to radiation, and are therefore increasingly sought after by providers and patients. Besides, patient education regarding the benefits of early diagnosis supports an active healthcare trend, which, in turn, raises demand for nuclear medicine diagnostic products. With healthcare systems focusing on time and accuracy in diagnostics, the market will be dominated by the diagnostics segment, boosting growth and expansion in the nuclear medicine market.

Regional Outlook of Nuclear Medicine Market

Nuclear Medicine Market By Region

Attribute	Detail
Leading Region	North America

North America holds the largest share in the nuclear medicine market due to a combination of high-end healthcare infrastructure, R&D spending, and prevalence of chronic illnesses. The region has several of the world's top-notch medical facilities and high emphasis on early disease diagnosis and precision medicine, thus driving the usage of nuclear medicine technology. It is also the foundation for industry giants and newcomers that form a competitive arena in which growth is being fueled at an extremely fast pace.

Among the leading causes for market leadership is increasing adoption of hybrid imaging equipment such as PET/CT and SPECT/CT that enhance patient outcomes and diagnostic efficiency. The technology is used at a larger scale in North American health centers, thereby strengthening the region's market leadership. In addition, good regulatory conditions coupled with governments’ support toward improving the quality of healthcare services strengthen growth in the nuclear medicine sector.

Analysis of Key Players in Nuclear Medicine Market

Key players in the global nuclear medicine market are investing in technological advancements, innovation, and forming alliances. Their objective is to improve the accuracy of testing, diversify their products, and gain a better market presence in order to be ahead of the curve in the evolving healthcare market.

Cardinal Health, Jubilant Pharma Company, The Bracco Group, Nordion (Canada) Inc., NTP Radioisotopes SOC Ltd., ECZACIBAŞI-MONROL, Lantheus, China lsotope & Radiation Corporation, Eckert & Ziegler Medical, Mallinckrodt plc, GE HealthCare, Blue Earth Diagnostics, NorthStar Medical Radioisotopes, LLC, B. J. Madan & Co, Curium Pharma, Novartis AG, Bayer AG are some of the leading players.

Each of these players has been profiled in the nuclear medicine industry research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments in Nuclear Medicine Market

In June 2025, GE HealthCare received U.S. FDA’s approval for its Vizamyl PET imaging agent for beta-amyloid detection. The updated label expands indications, facilitates quantitative analysis, and removes limitations such as monitoring patient response to anti-amyloid therapy. This improves diagnostic confidence and allows for precise treatment strategies.
In March 2025, Actinium Pharmaceuticals announced ATNM-400, a novel, non-PSMA targeting, first-in-class radiotherapy for prostate cancer. The ATNM-400 targets a different marker than Pluvicto, which is overexpressed in prostate cancer patients.

Nuclear Medicine Market Snapshot

Attribute	Detail
Size in 2024	US$ 18.6 Bn
Forecast Value in 2035	US$ 57.3 Bn
CAGR	10.8%
Forecast Period	2025-2035
Historical Data Available for	2020-2023
Quantitative Units	US$ Bn
Nuclear Medicine Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape	Competition Matrix Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Segmentation	Product Type Diagnostics Products SPECT Technetium-99m (TC-99m) Thallium-201 (Tl-201) Gallium-67 (GA-67) Iodine-123 (I-123) Others (Indium-111, etc.) PET Fluorine-18 (F-18) Rubidium-82 (Rb-82)/Strontium-82 (Sr-82) Nitrogen-13 (N-13) Others (C-11 (Carbon-11), etc.) Others (In-vitro Diagnostic kit, etc.) Therapeutic Products Alpha Emitters Radium-223 (RA-223) Others (Bismuth-213 (Bi-213), etc.) Beta Emitters Iodine-131 (I-131) Sodium Phosphate [32P] Yttrium-90 (Y-90) Samarium-153 (SM-153) Rhenium 186 (Re-186) Lutetium-177 (Lu-117) Others (Holmium-166 (Ho-166), etc.) Brachytherapy Cesium-131 (Cs-131) Iodine-125 (I-125) Palladium-103 (Pd-103) Iridium-192 (Ir-192) Application Cardiology Neurology Oncology Thyroid Lymphoma Bone Metastasis Endocrine Tumor Others (Autoimmune disease, etc.) End-user Hospitals and Clinics Diagnostic Centers Others (Research Laboratories, etc.)
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain The Netherlands China India Japan South Korea ASEAN Australia Brazil Mexico Argentina GCC Countries South Africa
Companies Profiled	Cardinal Health Jubilant Pharma Company The Bracco Group Nordion (Canada) Inc. NTP Radioisotopes SOC Ltd. ECZACIBAŞI-MONROL Lantheus China lsotope & Radiation Corporation Eckert & Ziegler Medical Mallinckrodt plc GE HealthCare Blue Earth Diagnostics NorthStar Medical Radioisotopes, LLC B. J. Madan & Co Curium Pharma Novartis AG Bayer AG Other prominent players
Customization Scope	Available upon request
Pricing	Available upon request

Frequently Asked Questions

How big was the global nuclear medicine market in 2024?

It was valued at US$ 18.6 Bn in 2024

What is the projected size of the nuclear medicine market by 2035?

It is projected to cross US$ 57.3 Bn by the end of 2035

What are the factors driving the nuclear medicine market?

Growing adoption of hybrid imaging systems and increased demand for early and accurate diagnosis

What is the nuclear medicine industry expected to grow during the forecast period?

It is anticipated to grow at a CAGR of 10.8% from 2025 to 2035

Which region is expected to dominate the nuclear medicine market during the forecast period?

North America is expected to account for the largest share from 2025 to 2035

Who are the prominent nuclear medicine providers?

Preface
- Market Definition and Scope
- Market Segmentation
- Key Research Objectives
- Research Highlights
Assumptions and Research Methodology
Executive Summary: Global Nuclear Medicine Market
Market Overview
- Introduction
  - Segment Definition
- Overview
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- Global Nuclear Medicine Market Analysis and Forecast, 2020-2035
  - Market Revenue Projections (US$ Bn)
Key Insights
- Regulatory Scenarios across Key Regions / Countries
- PESTLE Analysis
- Product & Brand Analysis
- Nuclear Medicine Product Launch/Approvals
- Pricing Analysis
- Technological Advancements
- Supply Chain Analysis
- Healthcare Expenditure by Country
- Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions, funding and investments)
Global Nuclear Medicine Market Analysis and Forecast, by Product Type
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Product Type, 2020-2035
  - Diagnostics Products
    - SPECT
      - Technetium-99m (TC-99m)
      - Thallium-201 (Tl-201)
      - Gallium-67 (GA-67)
      - Iodine-123 (I-123)
      - Others
    - PET
      - Fluorine-18 (F-18)
      - Rubidium-82 (Rb-82)/Strontium-82 (Sr-82)
      - Nitrogen-13 (N-13)
      - Others
    - Others
  - Therapeutic Products
    - Alpha Emitters
      - Radium-223 (RA-223)
      - Others
    - Beta Emitters
      - Iodine-131 (I-131)
      - Sodium Phosphate [32P]
      - Yttrium-90 (Y-90)
      - Samarium-153 (SM-153)
      - Rhenium 186 (Re-186)
      - Lutetium-177 (Lu-117)
      - Others
    - Brachytherapy
      - Cesium-131 (Cs-131)
      - Iodine-125 (I-125)
      - Palladium-103 (Pd-103)
      - Iridium-192 (Ir-192)
      - Others
- Market Attractiveness Analysis, by Product Type
Global Nuclear Medicine Market Analysis and Forecast, by Application
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Application, 2020-2035
  - Cardiology
  - Neurology
  - Oncology
  - Thyroid
  - Lymphoma
  - Bone Metastasis
  - Endocrine Tumor
  - Others
- Market Attractiveness Analysis, by Application
Global Nuclear Medicine Market Analysis and Forecast, by End-user
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by End-user, 2020-2035
  - Hospitals and Clinics
  - Diagnostic Centers
  - Others
- Market Attractiveness Analysis, by End-user
Global Nuclear Medicine Market Analysis and Forecast, by Region
- Key Findings
- Market Value Forecast, by Region, 2020-2035
  - North America
  - Europe
  - Asia Pacific
  - Latin America
  - Middle East & Africa
- Market Attractiveness Analysis, by Region
North America Nuclear Medicine Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Product Type, 2020-2035
  - Diagnostics Products
    - SPECT
      - Technetium-99m (TC-99m)
      - Thallium-201 (Tl-201)
      - Gallium-67 (GA-67)
      - Iodine-123 (I-123)
      - Others
    - PET
      - Fluorine-18 (F-18)
      - Rubidium-82 (Rb-82)/Strontium-82 (Sr-82)
      - Nitrogen-13 (N-13)
      - Others
    - Others
  - Therapeutic Products
    - Alpha Emitters
      - Radium-223 (RA-223)
      - Others
    - Beta Emitters
      - Iodine-131 (I-131)
      - Sodium Phosphate [32P]
      - Yttrium-90 (Y-90)
      - Samarium-153 (SM-153)
      - Rhenium 186 (Re-186)
      - Lutetium-177 (Lu-117)
      - Others
    - Brachytherapy
      - Cesium-131 (Cs-131)
      - Iodine-125 (I-125)
      - Palladium-103 (Pd-103)
      - Iridium-192 (Ir-192)
      - Others
- Market Value Forecast, by Application, 2020-2035
  - Cardiology
  - Neurology
  - Oncology
  - Thyroid
  - Lymphoma
  - Bone Metastasis
  - Endocrine Tumor
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospitals and Clinics
  - Diagnostic Centers
  - Others
- Market Value Forecast, by Country, 2020-2035
  - U.S.
  - Canada
- Market Attractiveness Analysis
  - By Product Type
  - By Application
  - By End-user
  - By Country
Europe Nuclear Medicine Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Product Type, 2020-2035
  - Diagnostics Products
    - SPECT
      - Technetium-99m (TC-99m)
      - Thallium-201 (Tl-201)
      - Gallium-67 (GA-67)
      - Iodine-123 (I-123)
      - Others
    - PET
      - Fluorine-18 (F-18)
      - Rubidium-82 (Rb-82)/Strontium-82 (Sr-82)
      - Nitrogen-13 (N-13)
      - Others
    - Others
  - Therapeutic Products
    - Alpha Emitters
      - Radium-223 (RA-223)
      - Others
    - Beta Emitters
      - Iodine-131 (I-131)
      - Sodium Phosphate [32P]
      - Yttrium-90 (Y-90)
      - Samarium-153 (SM-153)
      - Rhenium 186 (Re-186)
      - Lutetium-177 (Lu-137)
      - Others
    - Brachytherapy
      - Cesium-131 (Cs-131)
      - Iodine-125 (I-125)
      - Palladium-133 (Pd-133)
      - Iridium-192 (Ir-192)
      - Others
- Market Value Forecast, by Application, 2020-2035
  - Cardiology
  - Neurology
  - Oncology
  - Thyroid
  - Lymphoma
  - Bone Metastasis
  - Endocrine Tumor
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospitals and Clinics
  - Diagnostic Centers
  - Others
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - Germany
  - UK
  - France
  - Italy
  - Spain
  - The Netherlands
  - Rest of Europe
- Market Attractiveness Analysis
  - By Product Type
  - By Application
  - By End-user
  - By Country/Sub-region
Asia Pacific Nuclear Medicine Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Product Type, 2020-2035
  - Diagnostics Products
    - SPECT
      - Technetium-99m (TC-99m)
      - Thallium-201 (Tl-201)
      - Gallium-67 (GA-67)
      - Iodine-223 (I-223)
      - Others
    - PET
      - Fluorine-18 (F-18)
      - Rubidium-82 (Rb-82)/Strontium-82 (Sr-82)
      - Nitrogen-13 (N-13)
      - Others
    - Others
  - Therapeutic Products
    - Alpha Emitters
      - Radium-223 (RA-223)
      - Others
    - Beta Emitters
      - Iodine-131 (I-131)
      - Sodium Phosphate [32P]
      - Yttrium-90 (Y-90)
      - Samarium-153 (SM-153)
      - Rhenium 186 (Re-186)
      - Lutetium-177 (Lu-227)
      - Others
    - Brachytherapy
      - Cesium-131 (Cs-131)
      - Iodine-225 (I-225)
      - Palladium-223 (Pd-223)
      - Iridium-192 (Ir-192)
      - Others
- Market Value Forecast, by Application, 2020-2035
  - Cardiology
  - Neurology
  - Oncology
  - Thyroid
  - Lymphoma
  - Bone Metastasis
  - Endocrine Tumor
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospitals and Clinics
  - Diagnostic Centers
  - Others
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - China
  - India
  - Japan
  - South Korea
  - Australia
  - ASEAN
  - Rest of Asia Pacific
- Market Attractiveness Analysis
  - By Product Type
  - By Application
  - By End-user
  - By Country/Sub-region
Latin America Nuclear Medicine Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Product Type, 2020-2035
  - Diagnostics Products
    - SPECT
      - Technetium-99m (TC-99m)
      - Thallium-201 (Tl-201)
      - Gallium-67 (GA-67)
      - Iodine-123 (I-123)
      - Others
    - PET
      - Fluorine-18 (F-18)
      - Rubidium-82 (Rb-82)/Strontium-82 (Sr-82)
      - Nitrogen-29 (N-29)
      - Others
    - Others
  - Therapeutic Products
    - Alpha Emitters
      - Radium-223 (RA-223)
      - Others
    - Beta Emitters
      - Iodine-291 (I-291)
      - Sodium Phosphate [32P]
      - Yttrium-90 (Y-90)
      - Samarium-153 (SM-153)
      - Rhenium 186 (Re-186)
      - Lutetium-177 (Lu-297)
      - Others
    - Brachytherapy
      - Cesium-291 (Cs-291)
      - Iodine-125 (I-125)
      - Palladium-293 (Pd-293)
      - Iridium-192 (Ir-192)
      - Others
- Market Value Forecast, by Application, 2020-2035
  - Cardiology
  - Neurology
  - Oncology
  - Thyroid
  - Lymphoma
  - Bone Metastasis
  - Endocrine Tumor
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospitals and Clinics
  - Diagnostic Centers
  - Others
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Market Attractiveness Analysis
  - By Product Type
  - By Application
  - By End-user
  - By Country/Sub-region
Middle East & Africa Nuclear Medicine Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Product Type, 2020-2035
  - Diagnostics Products
    - SPECT
      - Technetium-99m (TC-99m)
      - Thallium-201 (Tl-201)
      - Gallium-67 (GA-67)
      - Iodine-123 (I-123)
      - Others
    - PET
      - Fluorine-18 (F-18)
      - Rubidium-82 (Rb-82)/Strontium-82 (Sr-82)
      - Nitrogen-13 (N-13)
      - Others
    - Others
  - Therapeutic Products
    - Alpha Emitters
      - Radium-223 (RA-223)
      - Others
    - Beta Emitters
      - Iodine-131 (I-131)
      - Sodium Phosphate [32P]
      - Yttrium-90 (Y-90)
      - Samarium-153 (SM-153)
      - Rhenium 186 (Re-186)
      - Lutetium-177 (Lu-347)
      - Others
    - Brachytherapy
      - Cesium-131 (Cs-131)
      - Iodine-125 (I-125)
      - Palladium-343 (Pd-343)
      - Iridium-192 (Ir-192)
      - Others
- Market Value Forecast, by Application, 2020-2035
  - Cardiology
  - Neurology
  - Oncology
  - Thyroid
  - Lymphoma
  - Bone Metastasis
  - Endocrine Tumor
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospitals and Clinics
  - Diagnostic Centers
  - Others
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - GCC Countries
  - South Africa
  - Rest of Middle East & Africa
- Market Attractiveness Analysis
  - By Product Type
  - By Application
  - By End-user
  - By Country/Sub-region
Competition Landscape
- Market Player - Competition Matrix (By Tier and Size of Companies)
- Market Share Analysis, by Company (2024)
- Company Profiles
  - Cardinal Health
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Jubilant Pharma Company
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - The Bracco Group
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Nordion (Canada) Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - NTP Radioisotopes SOC Ltd.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - ECZACIBAŞI-MONROL
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Lantheus
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - China lsotope & Radiation Corporation
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Eckert & Ziegler Medical
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Mallinckrodt plc
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - GE HealthCare
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Blue Earth Diagnostics
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - NorthStar Medical Radioisotopes, LLC
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - B. J. Madan & Co
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Curium Pharma
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Novartis AG
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Bayer AG
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments

List of Tables

Table 01: Global Nuclear Medicine Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 02: Global Nuclear Medicine Market Value (US$ Bn) Forecast, By Diagnostics Products, 2020 to 2035
Table 03: Global Nuclear Medicine Market Value (US$ Bn) Forecast, By SPECT, 2020 to 2035
Table 04: Global Nuclear Medicine Market Value (US$ Bn) Forecast, By PECT, 2020 to 2035
Table 05: Global Nuclear Medicine Market Value (US$ Bn) Forecast, By Therapeutic Products, 2020 to 2035
Table 06: Global Nuclear Medicine Market Value (US$ Bn) Forecast, By Alpha Emitters, 2020 to 2035
Table 07: Global Nuclear Medicine Market Value (US$ Bn) Forecast, By Beta Emitters, 2020 to 2035
Table 08: Global Nuclear Medicine Market Value (US$ Bn) Forecast, By Brachytherapy, 2020 to 2035
Table 09: Global Nuclear Medicine Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 10: Global Nuclear Medicine Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 11: Global Nuclear Medicine Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 12: North America - Nuclear Medicine Market Value (US$ Bn) Forecast, by Country, 2020 to 2035
Table 13: North America Nuclear Medicine Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 14: North America Nuclear Medicine Market Value (US$ Bn) Forecast, By Diagnostics Products, 2020 to 2035
Table 15: North America Nuclear Medicine Market Value (US$ Bn) Forecast, By SPECT, 2020 to 2035
Table 16: North America Nuclear Medicine Market Value (US$ Bn) Forecast, By PECT, 2020 to 2035
Table 17: North America Nuclear Medicine Market Value (US$ Bn) Forecast, By Therapeutic Products, 2020 to 2035
Table 18: North America Nuclear Medicine Market Value (US$ Bn) Forecast, By Alpha Emitters, 2020 to 2035
Table 19: North America Nuclear Medicine Market Value (US$ Bn) Forecast, By Beta Emitters, 2020 to 2035
Table 20: North America Nuclear Medicine Market Value (US$ Bn) Forecast, By Brachytherapy, 2020 to 2035
Table 21: North America Nuclear Medicine Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 22: North America Nuclear Medicine Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 23: Europe - Nuclear Medicine Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 24: Europe Nuclear Medicine Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 25: Europe Nuclear Medicine Market Value (US$ Bn) Forecast, By Diagnostics Products, 2020 to 2035
Table 26: Europe Nuclear Medicine Market Value (US$ Bn) Forecast, By SPECT, 2020 to 2035
Table 27: Europe Nuclear Medicine Market Value (US$ Bn) Forecast, By PECT, 2020 to 2035
Table 28: Europe Nuclear Medicine Market Value (US$ Bn) Forecast, By Therapeutic Products, 2020 to 2035
Table 29: Europe Nuclear Medicine Market Value (US$ Bn) Forecast, By Alpha Emitters, 2020 to 2035
Table 30: Europe Nuclear Medicine Market Value (US$ Bn) Forecast, By Beta Emitters, 2020 to 2035
Table 31: Europe Nuclear Medicine Market Value (US$ Bn) Forecast, By Brachytherapy, 2020 to 2035
Table 32: Europe Nuclear Medicine Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 33: Europe Nuclear Medicine Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 34: Asia Pacific - Nuclear Medicine Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 35: Asia Pacific Nuclear Medicine Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 36: Asia Pacific Nuclear Medicine Market Value (US$ Bn) Forecast, By Diagnostics Products, 2020 to 2035
Table 37: Asia Pacific Nuclear Medicine Market Value (US$ Bn) Forecast, By SPECT, 2020 to 2035
Table 38: Asia Pacific Nuclear Medicine Market Value (US$ Bn) Forecast, By PECT, 2020 to 2035
Table 39: Asia Pacific Nuclear Medicine Market Value (US$ Bn) Forecast, By Therapeutic Products, 2020 to 2035
Table 40: Asia Pacific Nuclear Medicine Market Value (US$ Bn) Forecast, By Alpha Emitters, 2020 to 2035
Table 41: Asia Pacific Nuclear Medicine Market Value (US$ Bn) Forecast, By Beta Emitters, 2020 to 2035
Table 42: Asia Pacific Nuclear Medicine Market Value (US$ Bn) Forecast, By Brachytherapy, 2020 to 2035
Table 43: Asia Pacific Nuclear Medicine Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 44: Asia Pacific Nuclear Medicine Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 45: Latin America - Nuclear Medicine Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 46: Latin America Nuclear Medicine Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 47: Latin America Nuclear Medicine Market Value (US$ Bn) Forecast, By Diagnostics Products, 2020 to 2035
Table 48: Latin America Nuclear Medicine Market Value (US$ Bn) Forecast, By SPECT, 2020 to 2035
Table 49: Latin America Nuclear Medicine Market Value (US$ Bn) Forecast, By PECT, 2020 to 2035
Table 50: Latin America Nuclear Medicine Market Value (US$ Bn) Forecast, By Therapeutic Products, 2020 to 2035
Table 51: Latin America Nuclear Medicine Market Value (US$ Bn) Forecast, By Alpha Emitters, 2020 to 2035
Table 52: Latin America Nuclear Medicine Market Value (US$ Bn) Forecast, By Beta Emitters, 2020 to 2035
Table 53: Latin America Nuclear Medicine Market Value (US$ Bn) Forecast, By Brachytherapy, 2020 to 2035
Table 54: Latin America Nuclear Medicine Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 55: Latin America Nuclear Medicine Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 56: Middle East & Africa - Nuclear Medicine Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 57: Middle East & Africa Nuclear Medicine Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 58: Middle East & Africa Nuclear Medicine Market Value (US$ Bn) Forecast, By Diagnostics Products, 2020 to 2035
Table 59: Middle East & Africa Nuclear Medicine Market Value (US$ Bn) Forecast, By SPECT, 2020 to 2035
Table 60: Middle East & Africa Nuclear Medicine Market Value (US$ Bn) Forecast, By PECT, 2020 to 2035
Table 61: Middle East & Africa Nuclear Medicine Market Value (US$ Bn) Forecast, By Therapeutic Products, 2020 to 2035
Table 62: Middle East & Africa Nuclear Medicine Market Value (US$ Bn) Forecast, By Alpha Emitters, 2020 to 2035
Table 63: Middle East & Africa Nuclear Medicine Market Value (US$ Bn) Forecast, By Beta Emitters, 2020 to 2035
Table 64: Middle East & Africa Nuclear Medicine Market Value (US$ Bn) Forecast, By Brachytherapy, 2020 to 2035
Table 65: Middle East & Africa Nuclear Medicine Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 66: Middle East & Africa Nuclear Medicine Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035

List of Figures

Figure 01: Global Nuclear Medicine Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 02: Global Nuclear Medicine Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 03: Global Nuclear Medicine Market Revenue (US$ Bn), by Diagnostics Products, 2020 to 2035
Figure 04: Global Nuclear Medicine Market Revenue (US$ Bn), by Therapeutic Products, 2020 to 2035
Figure 05: Global Nuclear Medicine Market Value Share Analysis, By Application, 2024 and 2035
Figure 06: Global Nuclear Medicine Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 07: Global Nuclear Medicine Market Revenue (US$ Bn), by Cardiology, 2020 to 2035
Figure 08: Global Nuclear Medicine Market Revenue (US$ Bn), by Neurology, 2020 to 2035
Figure 09: Global Nuclear Medicine Market Revenue (US$ Bn), by Oncology, 2020 to 2035
Figure 10: Global Nuclear Medicine Market Revenue (US$ Bn), by Thyroid, 2020 to 2035
Figure 11: Global Nuclear Medicine Market Revenue (US$ Bn), by Lymphoma, 2020 to 2035
Figure 12: Global Nuclear Medicine Market Revenue (US$ Bn), by Bone Metastasis, 2020 to 2035
Figure 13: Global Nuclear Medicine Market Revenue (US$ Bn), by Endocrine Tumor, 2020 to 2035
Figure 14: Global Nuclear Medicine Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 15: Global Nuclear Medicine Market Value Share Analysis, By End-user, 2024 and 2035
Figure 16: Global Nuclear Medicine Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 17: Global Nuclear Medicine Market Revenue (US$ Bn), by Hospitals and Clinics, 2020 to 2035
Figure 18: Global Nuclear Medicine Market Revenue (US$ Bn), by Diagnostic Centers, 2020 to 2035
Figure 19: Global Nuclear Medicine Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 20: Global Nuclear Medicine Market Value Share Analysis, By Region, 2024 and 2035
Figure 21: Global Nuclear Medicine Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 22: North America - Nuclear Medicine Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 23: North America - Nuclear Medicine Market Value Share Analysis, by Country, 2024 and 2035
Figure 24: North America - Nuclear Medicine Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 25: North America Nuclear Medicine Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 26: North America Nuclear Medicine Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 27: North America Nuclear Medicine Market Value Share Analysis, By Application, 2024 and 2035
Figure 28: North America Nuclear Medicine Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 29: North America Nuclear Medicine Market Value Share Analysis, By End-user, 2024 and 2035
Figure 30: North America Nuclear Medicine Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 31: Europe - Nuclear Medicine Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 32: Europe - Nuclear Medicine Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 33: Europe - Nuclear Medicine Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 34: Europe Nuclear Medicine Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 35: Europe Nuclear Medicine Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 36: Europe Nuclear Medicine Market Value Share Analysis, By Application, 2024 and 2035
Figure 37: Europe Nuclear Medicine Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 38: Europe Nuclear Medicine Market Value Share Analysis, By End-user, 2024 and 2035
Figure 39: Europe Nuclear Medicine Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 40: Asia Pacific - Nuclear Medicine Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 41: Asia Pacific - Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 42: Asia Pacific - Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 43: Asia Pacific Nuclear Medicine Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 44: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 45: Asia Pacific Nuclear Medicine Market Value Share Analysis, By Application, 2024 and 2035
Figure 46: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 47: Asia Pacific Nuclear Medicine Market Value Share Analysis, By End-user, 2024 and 2035
Figure 48: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 49: Latin America - Nuclear Medicine Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 50: Latin America - Nuclear Medicine Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 51: Latin America - Nuclear Medicine Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 52: Latin America Nuclear Medicine Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 53: Latin America Nuclear Medicine Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 54: Latin America Nuclear Medicine Market Value Share Analysis, By Application, 2024 and 2035
Figure 55: Latin America Nuclear Medicine Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 56: Latin America Nuclear Medicine Market Value Share Analysis, By End-user, 2024 and 2035
Figure 57: Latin America Nuclear Medicine Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 58: Middle East & Africa - Nuclear Medicine Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 59: Middle East & Africa - Nuclear Medicine Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 60: Middle East & Africa - Nuclear Medicine Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 61: Middle East & Africa Nuclear Medicine Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 62: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 63: Middle East & Africa Nuclear Medicine Market Value Share Analysis, By Application, 2024 and 2035
Figure 64: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 65: Middle East & Africa Nuclear Medicine Market Value Share Analysis, By End-user, 2024 and 2035
Figure 66: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, By End-user, 2025 to 2035